GlassScriptPhysician profile
Edilberto A Moreno
NPI 1457328510
$4,647.92
in general payments reported to CMS, 2019-2025
30 companies · $692 in 2025
The $692 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $250 · 2021: $740 · 2022: $976 · 2023: $1,006 · 2024: $552 · 2025: $692.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,249.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,046.47 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $448.12 | 2022-2025 | |
| Myovant Sciences INC. | $443.95 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $440.11 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $298.79 | 2020-2025 | Slynd |
| Therapeuticsmd, INC. | $257.62 | 2019-2022 | |
| Coopersurgical, INC. | $248.13 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Pfizer INC. | $231.65 | 2019-2024 | |
| Gynesonics, INC. | $126.57 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $117.06 | 2019-2024 | Aptima, Myosure Tissue Removal Device |
| Agile Therapeutics, INC. | $113.75 | 2021-2024 | Twirla |
| Ascend Therapeutics US, LLC | $113.70 | 2020-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $108.52 | 2020-2025 | |
| Millicent US INC | $84.59 | 2024-2025 | Femlyv, Intrarosa, Femring |
| Myriad Women'S Health, INC. | $77.64 | 2023 | Myrisk |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $75.26 | 2019-2025 | Veozah |
| Biogen, INC. | $54.61 | 2025 | Zurzuvae |
| Vertex Pharmaceuticals Incorporated | $50.64 | 2024-2025 | |
| Vertical Pharmaceuticals, LLC | $50.59 | 2019 | |
| Novo Nordisk INC | $49.53 | 2023-2024 | Wegovy |
| Ethicon US, LLC | $47.39 | 2021 | |
| Amag Pharmaceuticals, INC. | $38.45 | 2019 | |
| Smith+Nephew, INC. | $19.88 | 2022 | |
| Cosette Pharmaceuticals INC. | $18.29 | 2025 | Vyleesi |
| Avion Pharmaceuticals | $15.90 | 2021 | |
| Allergan, INC. | $15.09 | 2019 | |
| Evofem Biosciences, INC. | $14.16 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $13.89 | 2019 | |
| Duchesnay USA Incorporated | $13.80 | 2019 | |
| Minerva Surgical, INC | $13.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edilberto Moreno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.